DEVELOPMENT AND MANUFACTURING OF RECOMBINANT NANOPARTICLE VACCINES

Presented by Atin Tomar, President & CEO, CPL Biologicals Pvt. Ltd

Followed by Presented by Amélie Boulais, Vaccine Platform Marketing Manager, Sartorius Stedim Biotech

A recombinant vaccine technology platform based on highly purified, properly-folded protein antigens in stable well-defined Nanoparticles, enabling efficient and safe manufacture of vaccines against highly pathogenic targets. Nanoparticles are intrinsically immunogenic, producing both durable neutralizing antibodies and cellular immunity. The platform can be utilized for rapid response to potential pandemics as the time from identification of relevant viral gene sequence to final GMP drug product ready for human studies has been demonstrated to take less than 4 months for multiple vaccines.

The GMP drug substance manufacturing process for the platform largely utilizes single-use technologies. Single-use technologies and recombinant platform enables the utilization of the same manufacturing facility for multiple products with rapid change-over.